Highlights from

EAN 2019

European Academy of Neurology

Oslo 29 June - 2 July 2019

Factors influencing choice of prophylactic migraine therapy

Results of the PANORAMA study provide insights into the current treatment paradigm for migraine in Germany and reveal a disproportionately long patient-journey. The choice of prophylactic migraine therapy is determined by a large number of factors, with the guidelines seemingly playing only a marginal role.

Up till now, there were no data available about the therapeutic algorithms used in daily practice, the number of treatment options migraine patients have already tried, and the categories of patients in high need for new treatment options in Germany. Data was collected in PANORAMA, with 119 specialised German centres contributing for over 10 months. Each patient was interviewed to generate an individual centre profile, followed by a thorough database research to characterise the patient's current medical treatment. Also, an expert interview was done to define the significance of migraine therapy in the centre.

Of all treated patients per calendar quarter, 13.8% had migraine; about 88% of these patients were referred from other centres. The majority of patients (60%) had at least 4 migraine days per month and 13% had a chronic condition. An average of 43% at each site received prophylactic treatment, while 68% were using triptans. Choice of prophylactic therapy was determined by a wide range of factors: comorbidities 49.6%; demography/patient situation 47.1%; adverse reactions/tolerability 33.6%; concomitant medication 22.7%; patient's wish 18.5%; previous therapy 14.3%; effectiveness 10.1%; guidelines 10.1%; simple handling 6.7%.

  1. Koch M, et al. EAN 2019, EPR2041.

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.